NLRC4-MAS
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AB2 BioTadekinig alfa
AB2 BioTadekinig alfa
AB2 BioTadekinig alfa
Clinical Trials (3)
Total enrollment: 49 patients across 3 trials
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension
Start: Jan 2018Est. completion: May 202411 patients
Phase 3Completed
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
Start: Jul 2017Est. completion: Nov 202315 patients
Phase 3Completed
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Start: Feb 2015Est. completion: Jul 201623 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.